vs
Side-by-side financial comparison of Noble Corp plc (NE) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
Noble Corp plc is the larger business by last-quarter revenue ($764.4M vs $619.8M, roughly 1.2× QuidelOrtho Corp). Noble Corp plc runs the higher net margin — 11.3% vs -14.8%, a 26.1% gap on every dollar of revenue. On growth, QuidelOrtho Corp posted the faster year-over-year revenue change (-10.5% vs -17.6%). Over the past eight quarters, Noble Corp plc's revenue compounded faster (9.5% CAGR vs -6.6%).
Barnes & Noble Booksellers is an American bookseller with the largest number of retail outlets in the United States. The company operates approximately 700+ retail stores across the United States.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
NE vs QDEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $764.4M | $619.8M |
| Net Profit | $86.6M | $-91.8M |
| Gross Margin | — | — |
| Operating Margin | 5.6% | — |
| Net Margin | 11.3% | -14.8% |
| Revenue YoY | -17.6% | -10.5% |
| Net Profit YoY | -10.4% | — |
| EPS (diluted) | $0.54 | $-1.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $619.8M | ||
| Q4 25 | $764.4M | — | ||
| Q3 25 | $798.0M | $699.9M | ||
| Q2 25 | $848.7M | $613.9M | ||
| Q1 25 | $874.5M | $692.8M | ||
| Q4 24 | $927.3M | $707.8M | ||
| Q3 24 | $800.5M | $727.1M | ||
| Q2 24 | $692.8M | $637.0M |
| Q1 26 | — | $-91.8M | ||
| Q4 25 | $86.6M | — | ||
| Q3 25 | $-21.1M | $-733.0M | ||
| Q2 25 | $42.9M | $-255.4M | ||
| Q1 25 | $108.3M | $-12.7M | ||
| Q4 24 | $96.6M | $-178.4M | ||
| Q3 24 | $61.2M | $-19.9M | ||
| Q2 24 | $195.0M | $-147.7M |
| Q1 26 | — | — | ||
| Q4 25 | 5.6% | — | ||
| Q3 25 | 6.3% | -100.7% | ||
| Q2 25 | 15.9% | -29.4% | ||
| Q1 25 | 21.4% | 4.7% | ||
| Q4 24 | 18.4% | -14.2% | ||
| Q3 24 | 14.4% | 2.1% | ||
| Q2 24 | 30.3% | -18.4% |
| Q1 26 | — | -14.8% | ||
| Q4 25 | 11.3% | — | ||
| Q3 25 | -2.6% | -104.7% | ||
| Q2 25 | 5.1% | -41.6% | ||
| Q1 25 | 12.4% | -1.8% | ||
| Q4 24 | 10.4% | -25.2% | ||
| Q3 24 | 7.6% | -2.7% | ||
| Q2 24 | 28.1% | -23.2% |
| Q1 26 | — | $-1.35 | ||
| Q4 25 | $0.54 | — | ||
| Q3 25 | $-0.13 | $-10.78 | ||
| Q2 25 | $0.27 | $-3.77 | ||
| Q1 25 | $0.67 | $-0.19 | ||
| Q4 24 | $0.56 | $-2.54 | ||
| Q3 24 | $0.40 | $-0.30 | ||
| Q2 24 | $1.34 | $-2.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $471.4M | $140.4M |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $4.5B | $1.9B |
| Total Assets | $7.5B | $5.6B |
| Debt / EquityLower = less leverage | — | 1.33× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $140.4M | ||
| Q4 25 | $471.4M | — | ||
| Q3 25 | $477.9M | $98.1M | ||
| Q2 25 | $338.2M | $151.7M | ||
| Q1 25 | $303.8M | $127.1M | ||
| Q4 24 | $247.3M | $98.3M | ||
| Q3 24 | $391.9M | $143.7M | ||
| Q2 24 | $162.9M | $107.0M |
| Q1 26 | — | $2.5B | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $4.5B | — | ||
| Q3 25 | $4.5B | $2.0B | ||
| Q2 25 | $4.6B | $2.8B | ||
| Q1 25 | $4.7B | $3.0B | ||
| Q4 24 | $4.7B | $3.0B | ||
| Q3 24 | $4.7B | $3.2B | ||
| Q2 24 | $4.0B | $3.2B |
| Q1 26 | — | $5.6B | ||
| Q4 25 | $7.5B | — | ||
| Q3 25 | $7.6B | $5.7B | ||
| Q2 25 | $7.7B | $6.4B | ||
| Q1 25 | $7.9B | $6.5B | ||
| Q4 24 | $8.0B | $6.4B | ||
| Q3 24 | $8.0B | $6.8B | ||
| Q2 24 | $5.6B | $6.7B |
| Q1 26 | — | 1.33× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | — | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $187.1M | — |
| Free Cash FlowOCF − Capex | $35.4M | — |
| FCF MarginFCF / Revenue | 4.6% | — |
| Capex IntensityCapex / Revenue | 19.9% | — |
| Cash ConversionOCF / Net Profit | 2.16× | — |
| TTM Free Cash FlowTrailing 4 quarters | $432.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $187.1M | — | ||
| Q3 25 | $277.1M | $-45.5M | ||
| Q2 25 | $216.4M | $-46.8M | ||
| Q1 25 | $271.1M | $65.6M | ||
| Q4 24 | $136.2M | $63.7M | ||
| Q3 24 | $283.8M | $117.9M | ||
| Q2 24 | $106.8M | $-97.9M |
| Q1 26 | — | — | ||
| Q4 25 | $35.4M | — | ||
| Q3 25 | $139.5M | $-94.7M | ||
| Q2 25 | $99.8M | $-84.3M | ||
| Q1 25 | $157.5M | $9.4M | ||
| Q4 24 | $-4.4M | $16.5M | ||
| Q3 24 | $156.8M | $71.4M | ||
| Q2 24 | $-34.3M | $-133.2M |
| Q1 26 | — | — | ||
| Q4 25 | 4.6% | — | ||
| Q3 25 | 17.5% | -13.5% | ||
| Q2 25 | 11.8% | -13.7% | ||
| Q1 25 | 18.0% | 1.4% | ||
| Q4 24 | -0.5% | 2.3% | ||
| Q3 24 | 19.6% | 9.8% | ||
| Q2 24 | -4.9% | -20.9% |
| Q1 26 | — | — | ||
| Q4 25 | 19.9% | — | ||
| Q3 25 | 17.3% | 7.0% | ||
| Q2 25 | 13.7% | 6.1% | ||
| Q1 25 | 13.0% | 8.1% | ||
| Q4 24 | 15.2% | 6.7% | ||
| Q3 24 | 15.9% | 6.4% | ||
| Q2 24 | 20.4% | 5.5% |
| Q1 26 | — | — | ||
| Q4 25 | 2.16× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 5.05× | — | ||
| Q1 25 | 2.50× | — | ||
| Q4 24 | 1.41× | — | ||
| Q3 24 | 4.64× | — | ||
| Q2 24 | 0.55× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NE
| Floaters | $559.8M | 73% |
| Jackups | $145.5M | 19% |
| Service Other | $59.1M | 8% |
QDEL
| Labs | $353.1M | 57% |
| Immunohematology | $138.3M | 22% |
| Point of Care | $112.8M | 18% |
| Molecular Diagnostics | $7.8M | 1% |
